SOUTH SAN FRANCISCO, Calif., April 16, 2018 /PRNewswire/ — Sutro Biopharma’s first antibody drug conjugate (ADC) to treat solid tumors was highly effective against ovarian cancer in preclinical xenograft models and had an encouraging safety profile, according to studies presented today…
